Sanuwave
SUWANEE, GA · Biotechnology · 31 employees
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Sanuwave’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processe
Funding history
- Funding Round — $1.8M — Jul 2024
- Series seed — $4.6M — Feb 2024
- Series seed — $1.9M — Jan 2024
- Series seed — $3.0M — Aug 2023
- Series seed — $1.2M — May 2023
Recent signals
- Mar 13, 2026: SEC 8-K (4.02): On March 13, 2026, Sanuwave Health, Inc. disclosed that it engaged a third party to conduct a sales and use tax nexus study, which revealed a historical liability for state sales and use tax related to prior periods. This finding necessitated a non-reliance on previously issued financial statements, as management must now account for the identified tax liabilities. The audit committee, in consultation with Baker Tilly US, LLP and Marcum LLP, concluded this after an extensive review. This situation potentially impacts the company's financial position as it will need to collect and remit the sales and use tax going forward, indicating a significant ongoing compliance obligation.
- Jun 03, 2025: Sanuwave Appoints Dustin Libby as EVP of Commercial Operations
- Jul 02, 2024: Raised $1.8M
- Apr 01, 2024: SANUWAVE Health, Inc. Names Peter Sorensen as Chief Financial Officer
- Feb 05, 2024: Raised $4.6M in Series seed
- Jan 05, 2024: Raised $1.9M in Series seed
- Aug 07, 2023: Raised $3.0M in Series seed
- May 16, 2023: Raised $1.2M in Series seed
See plans & pricing → Track Sanuwave’s funding, hiring, and signals — with verified contacts — on Fundz.